BioCentury
ARTICLE | Company News

Eboo Pharmaceuticals, FPRT Bio, MentiNova, Michael J. Fox Foundation For Parkinson's Research neurology news

February 10, 2014 8:00 AM UTC

The foundation named Eboo, FPRT and MentiNova as the 2H13 participants in The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program, which presents participants' projects to investors. Eboo is testing oral delta opioid receptor agonist/mu opioid receptor (OPRM1; MOR) antagonist compounds to treat Parkinson's disease and dyskinesia related to dopamine replacement therapy. The company intends to begin a preclinical pharmacokinetics assessment next quarter for candidate compounds, which include DPI-289 and DPI-290. The compounds were originally developed at Burroughs Wellcome Co., which is now GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.).

FPRT is developing XPro1595, a dominant-negative inhibitor of tumor necrosis factor (TNF) alpha, for PD. The company said it hopes to begin clinical testing four months after completing its series A financing, which it hopes to close in May. FPRT has rights to the product from Xencor Inc. (NASDAQ:XNCR, Monrovia, Calif.)...